WO2004060270A8 - Compositions and methods for the diagnosis and treatment of tumor - Google Patents
Compositions and methods for the diagnosis and treatment of tumorInfo
- Publication number
- WO2004060270A8 WO2004060270A8 PCT/US2003/029126 US0329126W WO2004060270A8 WO 2004060270 A8 WO2004060270 A8 WO 2004060270A8 US 0329126 W US0329126 W US 0329126W WO 2004060270 A8 WO2004060270 A8 WO 2004060270A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tumor
- diagnosis
- compositions
- treatment
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003303144A AU2003303144A1 (en) | 2002-10-18 | 2003-10-15 | Compositions and methods for the diagnosis and treatment of tumor |
| CA002503043A CA2503043A1 (en) | 2002-10-18 | 2003-10-15 | Compositions and methods for the diagnosis and treatment of tumor |
| JP2004564724A JP2006516192A (en) | 2002-10-18 | 2003-10-15 | Compositions and methods for tumor diagnosis and treatment |
| EP03813488A EP1578996A4 (en) | 2002-10-18 | 2003-10-15 | Compositions and methods for the diagnosis and treatment of tumor |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41898802P | 2002-10-18 | 2002-10-18 | |
| US60/418,988 | 2002-10-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2004060270A2 WO2004060270A2 (en) | 2004-07-22 |
| WO2004060270A8 true WO2004060270A8 (en) | 2005-07-14 |
Family
ID=32712943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2003/029126 Ceased WO2004060270A2 (en) | 2002-10-18 | 2003-10-15 | Compositions and methods for the diagnosis and treatment of tumor |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1578996A4 (en) |
| JP (1) | JP2006516192A (en) |
| AU (1) | AU2003303144A1 (en) |
| CA (1) | CA2503043A1 (en) |
| WO (1) | WO2004060270A2 (en) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003065006A2 (en) * | 2002-01-31 | 2003-08-07 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cancer |
| EP1562969A4 (en) * | 2002-03-28 | 2006-07-05 | Bristol Myers Squibb Co | Novel human cell surface protein with immunoglobulin folds, bgs-19 |
| CA2483436A1 (en) * | 2002-04-23 | 2003-11-06 | University Of Georgia Research Foundation, Inc. | N-acetylglucosaminyltransferase vb coding sequence, recombinant cells and methods |
| JP2005230011A (en) | 2004-02-20 | 2005-09-02 | Samsung Electronics Co Ltd | Breast cancer-related protein, gene encoding the same, and protein and diagnostic method for breast cancer using the gene |
| US20050186577A1 (en) | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
| DK2319925T3 (en) | 2004-08-16 | 2018-11-05 | Quark Pharmaceuticals Inc | Therapeutic applications of RTP801 inhibitors |
| GB0422211D0 (en) * | 2004-10-06 | 2004-11-03 | Randox Lab Ltd | Method |
| US20080145369A1 (en) * | 2004-10-13 | 2008-06-19 | Ginette Serrero | Autocrine Growth Factor Receptors and Methods |
| JP2007008844A (en) * | 2005-06-29 | 2007-01-18 | Nippon Flour Mills Co Ltd | Monoclonal antibody specifically reacting with septin 2 protein, hybridoma producing the same, cancer detection method and cancer detection kit |
| DOP2007000015A (en) | 2006-01-20 | 2007-08-31 | Quark Biotech Inc | THERAPEUTIC USES OF RTP801 INHIBITORS |
| US20070237713A1 (en) | 2006-04-04 | 2007-10-11 | Fan Rong A | PCan065 Antibody Compositions and Methods of Use |
| US7723052B2 (en) | 2006-05-11 | 2010-05-25 | Quark Pharmaceuticals, Inc. | Screening systems utilizing RTP801 |
| AU2007253740A1 (en) * | 2006-05-18 | 2007-11-29 | Molecular Profiling Institute, Inc. | System and method for determining individualized medical intervention for a disease state |
| EP2026843A4 (en) | 2006-06-09 | 2011-06-22 | Quark Pharmaceuticals Inc | Therapeutic uses of inhibitors of rtp801l |
| EP2137205A2 (en) | 2007-02-26 | 2009-12-30 | Quark Pharmaceuticals, Inc. | Inhibitors of rtp801 and their use in disease treatment |
| WO2008148072A2 (en) * | 2007-05-24 | 2008-12-04 | The Brigham And Women's Hospital, Inc. | Disease-associated genetic variations and methods for obtaining and using same |
| US8614311B2 (en) | 2007-12-12 | 2013-12-24 | Quark Pharmaceuticals, Inc. | RTP801L siRNA compounds and methods of use thereof |
| EP2334790A1 (en) * | 2008-08-27 | 2011-06-22 | Oncotherapy Science, Inc. | Pancreatic cancer related gene ttll4 |
| KR20110128316A (en) | 2009-02-20 | 2011-11-29 | 가니메드 파마슈티칼스 아게 | Methods and Compositions for Diagnosis and Treatment of Cancer |
| NO2499161T3 (en) | 2009-11-11 | 2018-02-03 | ||
| WO2011150400A1 (en) * | 2010-05-28 | 2011-12-01 | New York Blood Center, Inc. | Nuclear scaffold protein stip/tfip11 target for cancer therapy |
| EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| NZ724296A (en) | 2011-05-13 | 2020-05-29 | Ganymed Pharmaceuticals Ag | Antibodies for treatment of cancer expressing claudin 6 |
| AP2015008365A0 (en) | 2012-12-05 | 2015-04-30 | Novartis Ag | Compositions and methods for antibodies targeting epo |
| ES3032013T3 (en) * | 2013-03-15 | 2025-07-14 | Translate Bio Inc | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| WO2015014376A1 (en) | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| JP2018525389A (en) | 2015-08-12 | 2018-09-06 | ノバルティス アーゲー | How to treat eye disorders |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| MX2019014027A (en) | 2017-05-24 | 2020-08-03 | Thoeris Gmbh | Use of glutamine synthetase for treating hyperammonemia. |
| EP3856226A1 (en) | 2018-09-28 | 2021-08-04 | President and Fellows of Harvard College | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
| US12274733B2 (en) | 2018-09-28 | 2025-04-15 | President And Fellows Of Harvard College | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
| JP7766904B2 (en) * | 2021-06-04 | 2025-11-11 | 地方独立行政法人東京都健康長寿医療センター | Pharmaceutical composition for treating prostate cancer |
| US12252518B2 (en) | 2023-01-06 | 2025-03-18 | Life Biosciences, Inc. | Methods of treating non-arteritic anterior ischemic optic neuropathy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8678501A (en) * | 2000-08-24 | 2002-03-04 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
| KR20040014392A (en) * | 2000-08-24 | 2004-02-14 | 제넨테크, 인크. | Compositions and Methods for the Diagnosis and Treatment of Tumor |
| EP1445317A3 (en) * | 2000-08-24 | 2004-12-15 | Genentech Inc. | Compositions and methods for the diagnosis and treatment of tumor |
-
2003
- 2003-10-15 EP EP03813488A patent/EP1578996A4/en not_active Withdrawn
- 2003-10-15 AU AU2003303144A patent/AU2003303144A1/en not_active Abandoned
- 2003-10-15 WO PCT/US2003/029126 patent/WO2004060270A2/en not_active Ceased
- 2003-10-15 JP JP2004564724A patent/JP2006516192A/en active Pending
- 2003-10-15 CA CA002503043A patent/CA2503043A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006516192A (en) | 2006-06-29 |
| EP1578996A4 (en) | 2007-12-19 |
| EP1578996A2 (en) | 2005-09-28 |
| AU2003303144A1 (en) | 2004-07-29 |
| CA2503043A1 (en) | 2004-07-22 |
| WO2004060270A2 (en) | 2004-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004030615A8 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| EP1571968A3 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| WO2004016225A8 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| WO2004045516A9 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| WO2004060270A8 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| EP1572091A3 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| EP1571968A4 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| WO2003057160A8 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| EP1572091A4 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| EP1553912A4 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| AU2003302892A1 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
| WO2003072035A8 (en) | Compositions and methods for the treatment of immune related diseases | |
| WO2004041170A9 (en) | Compositions and methods for the treatment of immune related diseases | |
| AU2002251841A1 (en) | Compositions and methods for the therapy and diagnosis of pancreatic cancer | |
| WO2004024097A9 (en) | Compositions and methods for the treatment of immune related diseases | |
| AU2002251844A1 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
| AU2003300368A1 (en) | Methods and compositions for the diagnosis, prognosis, and treatment of cancer | |
| AU2003290605A1 (en) | Compositions and methods for the diagnosis and treatment of sepsis | |
| AU2002311909A1 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| AU2002303219A1 (en) | Compositions and methods for the therapy and diagnosis of cancer | |
| WO2005003154A8 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| AU2002359330A1 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| AU2003237792A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| AU2003219160A1 (en) | Methods and compositions for the treatment of cancer | |
| AU2002313726A1 (en) | Compositions and methods for the therapy and diagnosis of breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2003303144 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2003813488 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2503043 Country of ref document: CA Ref document number: 2004564724 Country of ref document: JP |
|
| D17 | Declaration under article 17(2)a | ||
| WWP | Wipo information: published in national office |
Ref document number: 2003813488 Country of ref document: EP |